RET fusion driven (RETfus+) non-small cell lung cancer: a comprehensive genomic profiling study with histologic correlation
BackgroundFusion of the RET gene resulting in clinically significant Genomic Alteration (GA) occur in 1-2% of NSCLC in the United States and has emerged as a major target for RET inhibitors which are first line treatment options in the Stage 4 setting. RET fusions have also been well-described as ac...
Saved in:
| Main Authors: | Prashanth Ashok Kumar, Michael Connolly, Alina Basnet, Dean Pavlick, Richard Huang, Steven Graziano, Jeffrey Ross |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1477910/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer
by: Lei Wang, et al.
Published: (2025-01-01) -
Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01) -
Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case
by: Raffaella Pagliaro, et al.
Published: (2025-01-01) -
Use of selpercatinib in a patient with <i>RET</i>-mutated non-small cell lung cancer: case report
by: A. M. Kazakov, et al.
Published: (2024-05-01) -
Case Report: Histological Transformation to Atypical Carcinoid in RET Fusion-positive NSCLC Following Immune Therapy Resistance
by: Yu ZHANG, et al.
Published: (2025-05-01)